Clinical and Biological Characterization of Patients with Low/Intermediate-1 Risk Myelodysplastic Syndrome and Iron Overload

被引：0
|
作者：
Ivars, David [1 ]
Collado, Rosa [2 ]
Alguero, Carmen [1 ]
Carmen Tormos, M. [1 ]
Diaz, Laura [1 ]
Luis Garcia-Ghnenez, Jose [3 ]
Arrizabalaga, Beatriz [4 ]
Orero, Mayte [2 ]
Perez, Pedro [2 ]
Sanchez, Magdalena [2 ]
Angeles Ruiz, M. [5 ]
Yaguee, Nuria [5 ]
Sancho-Tello, Reyes [6 ]
Regadera, Ana [7 ]
Tormo, Mar [8 ]
Egea, Mercedes [2 ]
Vidal, Elena [2 ]
Enrique O'Connor, J. [1 ]
Saez, Guillermo T. [1 ]
Carbonell, Felix [2 ]
机构：
[1] Univ Valencia, Valencia, Spain
[2] Hosp Gen Univ Valencia, Biomed Diag Ctr, Hematol Serv, Valencia, Spain
[3] Biomed Network Res Ctr Rare Dis, CIBERER, Valencia, Spain
[4] Hosp Cruces, Baracaldo, Spain
[5] Hosp Francesc de Borja, Valencia, Spain
[6] Hosp Arnau Vilanova, Hematol Serv, Valencia, Spain
[7] Hosp Gen Requena, Hematol Serv, Valencia, Spain
[8] Hosp Clin, Valencia, Spain
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.4956.4956
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4956
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload
    Du, Yali
    Long, Zhangbiao
    Chen, Miao
    Han, Bing
    Hou, Bo
    Feng, Feng
    ACTA HAEMATOLOGICA, 2017, 138 (02) : 119 - 128
  • [2] Oxidative imbalance in low/intermediate-1-risk myelodysplastic syndrome patients: The influence of iron overload
    Ivars, David
    Teresa Orero, Maria
    Javier, Karla
    Diaz-Vico, Laura
    Luis Garcia-Gimenez, Jose
    Mena, Salvador
    Tormos, Carmen
    Egea, Mercedes
    Luis Perez, Pedro
    Arrizabalaga, Beatriz
    Angeles Ruiz, Maria
    Yague, Nuria
    Tormo, Mar
    Sancho-Tello, Reyes
    Gomes, Angela
    Alguero, Carmen
    Enrique O'Connor, Jose
    Saez, Guillermo T.
    Carbonell, Felix
    Collado, Rosa
    CLINICAL BIOCHEMISTRY, 2017, 50 (16-17) : 911 - 917
  • [3] OUTCOMES OF CONTINUED AZACITIDINE TREATMENT FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME IN IPSS LOW AND INTERMEDIATE-1
    Moon, J. H.
    Sohn, S. K.
    Cho, Y. Y.
    Kim, Y. K.
    Kim, H. J.
    Kim, M. K.
    Do, Y. R.
    Song, M. K.
    Lee, W. K.
    Lee, S. M.
    Kim, H.
    Won, J. H.
    Yeon, J. Deok
    HAEMATOLOGICA, 2012, 97 : 141 - 141
  • [4] Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes
    Garcia-Manero, Guillermo
    Diez-Campelo, Maria
    Vellenga, Edo
    Jacoby, Meagan A.
    Merchan, Brayan
    Breems, Dimitri
    Cortelezzi, Agostino
    Doronin, Vadim
    Gomez, Valle
    Beckers, Marielle
    Della Porta, Matteo Giovanni
    Varsos, Helen
    Xiu, Liang
    DeAngelis, Nikki
    Nnane, Ivo
    Rose, Esther
    van Eygen, Koen
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (04) : E111 - E114
  • [5] Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Xiao, Lianchun
    Najla, Al Ali
    Mishra, Asmita
    Padron, Eric
    Lancet, Jeffrey E.
    Bryan, Jeffery
    Prescott, Hillary
    Steensma, David P.
    Sekeres, Mikkael A.
    Roboz, Gail J.
    List, Alan
    Kantarjian, Hagop M.
    Komrokji, Rami S.
    BLOOD, 2013, 122 (21)
  • [6] Cytogenetic Evolution in Patients with IPSS Low and Intermediate-1 Risk. Study from the Spanish Group of Myelodysplastic Syndrome
    Marcel Merchan, Brayan
    Ortega, Margarita
    Jose Llamas-Poyato, Mara
    Cortes, Montserrat
    Arnan, Montserrat
    Cervero, Carlos
    Montoro, Julia
    Gimenez, Teresa
    Lopez, Mara
    Arenillas, Leonor
    Valcarcel, David
    BLOOD, 2014, 124 (21)
  • [7] ARCADE (20090160): A randomized controlled trial of darbepoetin alpha in anemic patients with low or intermediate-1 risk myelodysplastic syndrome (MDS)
    Gasal, E.
    Pan, C.
    Tankersley, C.
    LEUKEMIA RESEARCH, 2013, 37 : S166 - S167
  • [8] ACQUISITION OF CYTOGENETIC ABNORMALITIES IN PATIENTS WITH IPSS LOW AND INTERMEDIATE-1 RISK. STUDY FROM THE SPANISH GROUP OF MYELODYSPLASTIC SYNDROME
    Merchan, B.
    Ortega, M.
    Llamas-Poyato, M. J.
    Cortes, M.
    Arnan, M.
    Cervero, C.
    Montoro, J.
    Gimenez, T.
    Lopez, M.
    Arenillas, L.
    Valcarcel, D.
    LEUKEMIA RESEARCH, 2015, 39 : S136 - S136
  • [9] Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure.
    Jabbour, Elias J.
    Daver, Naval G.
    Dong, Tina
    Kadia, Tapan M.
    O'Brien, Susan
    Cortes, Jorge E.
    Ravandi, Farhad
    Pemmaraju, Naveen
    Ghanem, Hady
    Faderl, Stefan
    Borthakur, Gautam
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2012, 120 (21)
  • [10] Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome
    Chien, Kelly S.
    Kim, Kunhwa
    Nogueras-Gonzalez, Graciela M.
    Borthakur, Gautam
    Naqvi, Kiran
    Daver, Naval G.
    Montalban-Bravo, Guillermo
    Cortes, Jorge E.
    DiNardo, Courtney D.
    Jabbour, Elias
    Alvarado, Yesid
    Andreeff, Michael
    Bose, Prithviraj
    Jain, Nitin
    Kadia, Tapan M.
    Huang, Xuelin
    Sheppard, Kimberly B.
    Klingner-Winton, Cheri
    Pierce, Sherry A.
    Dong, Xiao Qin
    Soltysiak, Kelly A.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 195 (03) : 378 - 387
12345